Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bingliancao lozenge
- Development stage
- Phase 2
- Lead developer
- Boji Medical
- Administration
- Buccal
01
Overview
Bingliancao lozenge is a traditional Chinese medicine (TCM) developed by Guangzhou Boji Medical & Biotechnological Co., Ltd. for the treatment of recurrent aphthous stomatitis (RAS). It is specifically indicated for patients presenting with the 'gastrointestinal heat' pattern, a diagnostic category in TCM associated with oral ulceration. The drug is formulated as a lozenge for local administration, intended to reduce pain and accelerate the healing of oral ulcers. It is currently undergoing Phase III clinical trials in China to evaluate its efficacy and safety compared to placebo in adults with mild RAS.
- Other names
- Bingliancao hanpian冰莲草含片
Beyond the preview
Go deeper on Bingliancao lozenge.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bingliancao lozenge.